Wegener's nodules (Pulmonary nodules in vasculitis) - Symptoms, Causes, Treatment & Prevention

Overview

Wegener’s nodules refer to pulmonary (lung) nodules that develop in the context of Granulomatosis with polyangiitis (GPA), formerly called Wegener’s granulomatosis. GPA is an autoimmune small‑vessel vasculitis that can affect the upper airway, lungs, kidneys, and other organs. When the disease involves the lungs, it often produces one or more round or irregularly shaped nodules that may cavitate (form a hollow center).

Although GPA is rare, it is one of the more common systemic vasculitides in adults:

• Incidence: 10–20 new cases per million people per year worldwide.¹
• Peak age: 40–65 years, but it can occur at any age, including children.
• Sex distribution: Slight male predominance (≈55 % male).

Pulmonary nodules are seen in up to 70 % of patients with active GPA, and many are asymptomatic, discovered incidentally on imaging performed for other reasons.²

Symptoms

Symptoms arise from the lung nodules themselves, from inflammation of surrounding tissue, or from systemic vasculitis. Not every person will have all of these symptoms.

Respiratory symptoms

• Cough – usually dry, but may become productive if the nodule cavitates.
• Hemoptysis – coughing up blood; can be mild to massive depending on cavity size.
• Shortness of breath (dyspnea) – worsens with exertion; may be the first sign of extensive lung involvement.
• Chest pain – often pleuritic (sharp, worsens with breathing) when a nodule is near the pleura.

Systemic signs

• Fever – low‑grade, often in the setting of active vasculitis.
• Fatigue & malaise – common in chronic inflammatory diseases.
• Weight loss – unintended loss >5 % of body weight over 3–6 months.
• Night sweats – especially in active disease.

Other organ involvement (helps differentiate GPA from isolated lung nodules)

• Upper airway: chronic sinusitis, nasal crusting, otitis media, or saddle‑nose deformity.
• Kidneys: hematuria, proteinuria, rapidly progressive glomerulonephritis.
• Skin: palpable purpura, ulcerations, or livedo reticularis.
• Eyes: scleritis, conjunctivitis.

Causes and Risk Factors

GPA is an autoimmune disease; the exact trigger is unknown, but several mechanisms and risk factors have been identified.

Immunologic cause

• Antineutrophil cytoplasmic antibodies (ANCA) – Most patients have PR3‑ANCA (proteinase‑3) directed antibodies, which activate neutrophils and cause vessel damage.³

Genetic predisposition

• HLA‑DPB1*04 and HLA‑DQ variants have been linked to higher susceptibility, though the absolute risk remains low.

Environmental exposures

• Silica dust (occupational exposure in mining, stone‑cutting, construction) is associated with a 2–3‑fold increased risk of GPA.⁴
• Chronic nasal carriage of Staphylococcus aureus may provoke immune activation.

Other risk factors

• Age 40–65 (peak incidence).
• Male sex (modest increase).
• History of other autoimmune diseases (e.g., rheumatoid arthritis, lupus) – shared genetic pathways.

Diagnosis

Diagnosing pulmonary nodules related to GPA requires a combination of clinical assessment, imaging, serology, and sometimes tissue biopsy.

Step‑by‑step diagnostic pathway

1. Clinical evaluation – Detailed history (sinus, ear, kidney symptoms), physical exam, and assessment of systemic signs.
2. Laboratory tests
   • ANCA testing – PR3‑ANCA (c‑ANCA) is positive in ~80‑90 % of GPA patients with lung disease.⁵
   • Complete blood count (CBC) – may show anemia or leukocytosis.
   • Renal panel – serum creatinine, urinalysis for hematuria/proteinuria.
   • Inflammatory markers – ESR, CRP are often elevated.
3. Imaging
   • Chest X‑ray – May reveal multiple nodules, cavitation, or infiltrates.
   • High‑resolution CT (HRCT) – Gold standard for characterising nodules (size, margin, cavitation, distribution). Typical pattern: multiple bilateral nodules ranging from 0.5 cm to >5 cm, often with a halo of ground‑glass opacity.⁶
4. Bronchoscopy with bronchoalveolar lavage (BAL) – Helps exclude infection (especially fungal or mycobacterial) and can yield cytology.
5. Biopsy
   • CT‑guided percutaneous needle biopsy – provides tissue for histopathology (necrotizing granulomatous inflammation, vasculitis).
   • Video‑assisted thoracoscopic surgery (VATS) – reserved for nondiagnostic percutaneous samples.
6. Additional organ assessment – ENT examination, renal ultrasound, or kidney biopsy if renal involvement is suspected.

Diagnosis is confirmed when there is (1) compatible clinical picture, (2) positive PR3‑ANCA, and (3) characteristic radiologic or histologic evidence of necrotizing granulomatous vasculitis.

Treatment Options

Therapy aims to suppress the immune response, eradicate active inflammation, and preserve organ function. Treatment is usually divided into an induction phase (rapid control) and a maintenance phase (prevent relapse).

Induction therapy

• High‑dose glucocorticoids – Prednisone 1 mg/kg/day (max 60 mg) or IV methylprednisolone 500–1000 mg daily for 3 days for severe disease.⁷
• Cyclophosphamide – Oral (2 mg/kg/day) or IV pulse (15 mg/kg every 2–3 weeks). Requires monitoring for cytopenias, hemorrhagic cystitis, and secondary malignancy.
• Rituximab – Anti‑CD20 monoclonal antibody, 375 mg/m² weekly for 4 weeks or 1 g on days 1 and 15. Equivalent efficacy to cyclophosphamide for induction and preferred in patients desiring fertility preservation.⁸
• Plasma exchange (PLEX) – Considered for rapidly progressive glomerulonephritis or severe pulmonary hemorrhage (guidelines are evolving).

Maintenance therapy (after remission)

• Azumatinib – Not used; the correct agents are azathioprine, methotrexate, or mycophenolate mofetil, usually for 18–24 months.
• Rituximab – 500 mg IV every 6 months, an alternative to azathioprine.
• Low‑dose glucocorticoids – Tapered slowly; many patients stay on <10 mg prednisone/day or less.

Supportive and adjunctive measures

• Prophylaxis for Pneumocystis jirovecii pneumonia (PJP) with trimethoprim‑sulfamethoxazole while on high‑dose steroids/cyclophosphamide.
• Vaccinations: Influenza annually, pneumococcal (PCV20 or PCV15 + PPSV23), COVID‑19.
• Bone health: Calcium + Vitamin D plus bisphosphonate if steroids >3 months.
• Smoking cessation – critical to minimize lung injury.

Living with Wegener’s Nodules (Pulmonary Nodules in Vasculitis)

Managing a chronic vasculitis involves medical, emotional, and practical strategies.

Daily self‑care

• Medication adherence – Use a pill organizer or smartphone reminders; never stop steroids abruptly.
• Symptom log – Record cough, breathlessness, fevers, or new ENT/kidney symptoms; share with your rheumatologist.
• Pulmonary hygiene – Deep‑breathing exercises, incentive spirometry, and staying active (walking, swimming) to improve lung capacity.
• Hydration & nutrition – Adequate fluids and a balanced diet support immune function and mitigate steroid‑related weight gain.

Monitoring and follow‑up

• Clinic visits every 1–3 months during induction, then every 3–6 months for maintenance.
• Repeat chest CT at 3‑month intervals initially, then annually if stable.
• Regular labs: CBC, renal panel, liver function, ESR/CRP, and ANCA titers (trend, not sole marker).

Psychosocial support

• Consider counseling or support groups (e.g., Vasculitis Foundation). Chronic illness can lead to anxiety or depression.
• Financial counseling – many treatments (rituximab, biologics) are high cost; explore insurance or patient‑assistance programs.

Work and lifestyle adjustments

• Discuss workplace accommodations if you experience fatigue or need frequent bathroom breaks (due to steroid‑related glucose changes).
• Avoid high‑altitude or dusty environments until lung nodules are stable.
• Plan for flu season and travel vaccinations early.

Prevention

Because GPA is autoimmune, true primary prevention is not possible, but several steps can reduce triggers and complications.

• Avoid silica exposure – Use protective masks and proper ventilation in at‑risk occupations.
• Prompt treatment of sinus infections – Reduces chronic bacterial colonisation that may amplify autoimmunity.
• Smoking cessation – Lowers risk of pulmonary complications and improves response to therapy.
• Vaccination adherence – Reduces respiratory infections that could mimic or exacerbate vasculitis flares.
• Regular medical follow‑up – Early detection of relapse minimizes organ damage.

Complications

If left untreated or poorly controlled, pulmonary nodules and systemic GPA can lead to serious outcomes.

• Massive hemoptysis – Cavitary nodules can erode vessels, causing life‑threatening bleeding.
• Progressive pulmonary fibrosis – Chronic inflammation may scar lung tissue, reducing diffusion capacity.
• Renal failure – Rapidly progressive glomerulonephritis occurs in up to 30 % of patients; 10‑15 % progress to end‑stage renal disease.
• Upper airway collapse – Subglottic stenosis can cause stridor and require surgical intervention.
• Secondary infections – Immunosuppressive therapy predisposes to bacterial, fungal, and viral infections.
• Medication toxicity – Cyclophosphamide‑related bladder cancer, rituximab infusion reactions, steroid‑induced osteoporosis, diabetes, and cataracts.

When to Seek Emergency Care

---

**References**

1. Yates M, et al. “Epidemiology of granulomatosis with polyangiitis.” *Clin Exp Rheumatol*. 2016;34(5):757‑765. PMCID: PMC4891240
2. Cleveland Clinic. “Granulomatosis with Polyangiitis (Wegener’s).” Updated 2023. Link
3. CDC. “ANCA-Associated Vasculitis.” 2022. PDF
4. Olivier S, et al. “Silica exposure and risk of ANCA-associated vasculitis.” *Occup Environ Med*. 2015;72(5):361‑368. PMCID: PMC4526504
5. Mayo Clinic. “Antineutrophil cytoplasmic antibody (ANCA) test.” 2022. Link
6. CDC. “Diagnostic Tests for Lung Disease.” 2023. Link
7. Stone JH, et al. “Rituximab versus Cyclophosphamide for ANCA-Associated Vasculitis.” *N Engl J Med*. 2010;363:221‑232. Link
8. Walsh M, et al. “Long‑term outcomes of rituximab in GPA.” *Lancet Rheumatology*. 2021;3:e75‑e84.